SCHEMBL3264416

SCHEMBL3264416

O=C1NCc2c1c1c(c3[nH]c4ccccc4c23)CCc2cc(O)ccc2-1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K9 P80192 8/20 0.77
MAP3K11 Q16584 8/20 0.77
ROCK2 O75116 7/20 0.65
PRKCA P17252 6/20 0.65
PRKCQ Q04759 5/20 0.65
PRKCD Q05655 5/20 0.65
PRKD3 O94806 4/20 0.65
PRKCG P05129 4/20 0.65
PRKCB P05771 4/20 0.65
PRKCH P24723 4/20 0.65
PRKCI P41743 4/20 0.65
PRKCE Q02156 4/20 0.65
PRKCZ Q05513 4/20 0.65
PRKD1 Q15139 4/20 0.65
MAP3K10 Q02779 4/20 0.65
KDR P35968 3/20 0.65
MAP3K5 Q99683 2/20 0.65
GLI1 P08151 2/20 0.65
GLI2 P10070 2/20 0.65
NTRK1 P04629 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2755778 0.85 MAP3K9 (1.00) MAP3K9MAP3K11ROCK2PRKCAPRKCQ
SCHEMBL2755774 0.80 MAP3K9 (0.79) MAP3K9MAP3K11ROCK2PRKCAPRKCQ
SCHEMBL6627111 0.80 MAP3K9 (0.76) MAP3K9MAP3K11ROCK2PRKCAPRKCQ
SCHEMBL3072275 0.79 MAP3K11 (1.00) MAP3K9MAP3K11ROCK2PRKCAPRKCQ
SCHEMBL6629443 0.76 MAP3K9 (0.76) MAP3K9MAP3K11ROCK2PRKCAPRKCQ
SCHEMBL2755758 0.74 KDR (0.68) MAP3K9MAP3K11ROCK2PRKCAPRKCQ
SCHEMBL13178828 0.74 MAP3K9 (0.44) MAP3K9MAP3K11ROCK2PRKCAPRKCQ
Staurosporinone SCHEMBL5440281 0.74 MAP3K11 (1.00) MAP3K9MAP3K11ROCK2PRKCAPRKCQ
Staurosporinone SCHEMBL29374983 0.74 MAP3K11 (1.00) MAP3K9MAP3K11ROCK2PRKCAPRKCQ
Staurosporinone SCHEMBL29389399 0.74 MAP3K11 (1.00) MAP3K9MAP3K11ROCK2PRKCAPRKCQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383813-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2013-02-26 US disclosed
US-20120004253-A1 Novel Fused Pyrrolocarbazoles CEPHALON, INC. (US) 2012-01-05 US disclosed
US-8084472-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2011-12-27 US disclosed
US-8084472-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2011-12-27 US disclosed
US-8044064-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2011-10-25 US disclosed
US-8044064-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2011-10-25 US disclosed
EP-1704148-B1 NOVEL FUSED PYRROLOCARBAZOLES CEPHALON INC (US) 2011-03-02 EP disclosed
US-20100152196-A1 Novel Fused Pyrrolocarbazoles CEPHALON, INC. (US) 2010-06-17 US disclosed
US-20100152196-A1 Novel Fused Pyrrolocarbazoles CEPHALON, INC. (US) 2010-06-17 US disclosed
US-7671064-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2010-03-02 US disclosed
US-20090186888-A1 NOVEL FUSED PYRROLOCARBAZOLES CEPHALON, INC. (US) 2009-07-23 US disclosed
US-7514440-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2009-04-07 US disclosed
US-7514440-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2009-04-07 US disclosed
US-20070203135-A1 Novel Fused Pyrrolocarbazoles CEPHALON, INC. (US) 2007-08-30 US disclosed
US-20070203135-A1 Novel Fused Pyrrolocarbazoles CEPHALON, INC. (US) 2007-08-30 US disclosed
US-7241779-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2007-07-10 US disclosed
US-7241779-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2007-07-10 US disclosed
US-7169802-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2007-01-30 US disclosed
US-7169802-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2007-01-30 US disclosed
WO-2005063764-A2 FUSED PYRROLOCARBAZOLES AND METHODS FOR THE PREPARATION THEREOF CEPHALON, INC. (US) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152196-A1 Novel Fused Pyrrolocarbazoles PC, PYCR1, CYP11B2 MAP3K9 3651/4885MAP3K11 3535/4885ROCK2 1453/4885
US-20120004253-A1 Novel Fused Pyrrolocarbazoles PC, PYCR1, CYP11B2 MAP3K9 3651/4885MAP3K11 3535/4885ROCK2 1453/4885
US-20090186888-A1 NOVEL FUSED PYRROLOCARBAZOLES PC, PYCR1, CYP11B2 MAP3K9 3651/4885MAP3K11 3535/4885ROCK2 1453/4885
US-20070203135-A1 Novel Fused Pyrrolocarbazoles PC, PYCR1, CYP11B2 MAP3K9 3651/4885MAP3K11 3535/4885ROCK2 1453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.